Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
HS-10342
i
Other names:
HS-10342, HS 10342, HS10342
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Jiangsu Hansoh Pharma
Drug class:
CDK4/6 inhibitor
Related drugs:
‹
palbociclib (222)
abemaciclib (80)
ribociclib (62)
dalpiciclib (11)
trilaciclib (3)
PRT3645 (3)
bireociclib (2)
HX301 (2)
CS3002 (1)
GLR2007 (1)
tibremciclib (1)
FCN-437 (1)
G1T38 (1)
ETH-155008 (0)
FLX925 (0)
SPH4336 (0)
SRX3177 (0)
TY-302 (0)
Undisclosed CDK4/6 inhibitor (0)
BPI-1178 (0)
palbociclib (222)
abemaciclib (80)
ribociclib (62)
dalpiciclib (11)
trilaciclib (3)
PRT3645 (3)
bireociclib (2)
HX301 (2)
CS3002 (1)
GLR2007 (1)
tibremciclib (1)
FCN-437 (1)
G1T38 (1)
ETH-155008 (0)
FLX925 (0)
SPH4336 (0)
SRX3177 (0)
TY-302 (0)
Undisclosed CDK4/6 inhibitor (0)
BPI-1178 (0)
›
Associations
News
Trials
Filter by
Latest
4years
A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=20, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
4 years ago
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
HS-10342
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.